ImaginAb

Monoclonal antibodies (mAbs) are a proven strategy for generating incredibly selective targeting agents. ImaginAb harnesses the specificity of mAbs to engineer small, highly targeted proteins for imaging important molecular targets with Positron Emission Tomography (PET). ImaginAb’s technology produces actionable data that increases diagnostic precision, improves treatment decisions in the clinical setting, and enhances the development of new therapeutic drugs. ImaginAb has utilized this strategy to generate a rich pipeline of in vivo imaging agents in oncology and immunology, both as stand-alone clinical products and in partnership with select biopharmaceutical companies.